ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
유리체망막 질환 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 성장률(CAGR) 7.9%로 63억 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 연령 관련 황반변성 유병률 증가, 당뇨망막병증 유병률 증가, 재생 줄기세포 치료에 대한 투자 증가, 안과 질환에 대한 의료비 지출 증가, 망막 질환의 조기 발견에 대한 인식 증가, 정부 지원책 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 AI를 활용한 망막질환 감지, 로봇 보조 유리체망막 수술, 나노기술 기반 약물전달 시스템, 실시간 안구 모니터링용 스마트 콘택트렌즈, 초고해상도 보상 광학 이미징, 생분해성 유리체내 임플란트 등이 있습니다.
당뇨망막병증의 유병률 증가는 향후 몇 년 동안 유리체망막 질환 시장의 성장을 촉진할 것으로 예상됩니다. 당뇨망막병증은 당뇨병 환자에서 고혈당이 장기간 지속되면서 망막 혈관이 손상되어 발생하는 안질환입니다. 이 질환은 당뇨병 환자 수의 증가로 인해 점점 더 흔해지고 있으며, 주요 원인은 좌식 생활습관과 불충분한 혈당 조절로 인해 망막 혈관 손상을 초래합니다. 유리체 질환 치료는 유리체 출혈, 견인성 망막박리 등의 문제를 해결함으로써 시력을 유지하고 망막의 추가 손상을 최소화하는 당뇨망막병증 관리에 필수적입니다. 예를 들어, 2024년 10월 호주 정부 기관인 호주 보건 복지 연구소(Australian Institute of Health and Welfare)는 2022-23년 사이에 검진을 받은 원주민의 1.8%가 당뇨망막병증 치료를 받을 것으로 예상하고 있습니다. 표준화된 치료율은 1.3%인 반면, 비원주민 호주인의 치료율은 1.5%로 보고했습니다. 따라서 당뇨망막병증 발생률의 증가는 유리체망막 질환 시장 확대에 기여하고 있습니다.
유리체망막 질환 시장의 주요 기업들은 메토트렉세이트 기반 치료제와 같이 희귀하고 공격적인 망막암의 일종인 원발성 유리체망막 림프종을 표적으로 하는 첨단 치료제를 개발하고 있습니다. 이 치료법은 화학요법인 메토트렉세이트의 유리체내 투여를 통해 망막과 유리체의 암세포를 억제하여 집중적이고 효과적인 치료를 제공합니다. 예를 들어, 2022년 12월 미국 생명공학 기업 알데이라 테라퓨틱스(Aldeira Therapeutics)는 ADX-2191에 대한 FDA와의 신약허가신청(pre-NDA) 미팅을 성공적으로 마쳤다고 발표했습니다. ADX-2191은 원발성 유리체망막 림프종(PVRL)을 치료하기 위해 고안된 새로운 방부제 없는 메토트렉세이트 제제로, 이 희귀 질환에 대한 유망한 해결책을 제시할 것으로 기대됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 유리체망막 질환 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 유리체망막 질환 시장 : 성장률 분석
세계의 유리체망막 질환 시장 실적 : 규모와 성장, 2019-2024
세계의 유리체망막 질환 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 유리체망막 질환 전체 시장(TAM)
제6장 시장 세분화
세계의 유리체망막 질환 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
망막렬공
망막박리
당뇨망막병증
황반변성증
황반원공
기타 유형
세계의 유리체망막 질환 시장 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
디지털 형광 안저조영검사
광간섭단층촬영
하이델베르크 망막 단층촬영
인도시아닌 그린 형광 안저조영검사
기타 진단
세계의 유리체망막 질환 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
수술
약
기타 치료법
세계의 유리체망막 질환 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
온라인 약국
소매 약국
세계의 유리체망막 질환 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종사용자
세계의 유리체망막 질환 시장 망막렬공 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
위축성 망막렬공
망막렬공
편자형 망막렬공
거대 망막렬공
세계의 유리체망막 질환 시장 망막박리 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
렬공원성 망막박리
견인성 망막박리
삼출성 망막박리
세계의 유리체망막 질환 시장 당뇨망막병증 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
비증식성 당뇨망막병증
증식성 당뇨망막병증
당뇨병성황반부종
세계의 유리체망막 질환 시장황반변성증 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
건성황반변성증
습성황반변성증
세계의 유리체망막 질환 시장 황반원공 하위 세분화(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
전층 황반원공
층상 황반원공
견인성 황반원공
세계의 유리체망막 질환 시장, 기타 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
망막전막
망막정맥폐쇄증
망막 동맥 폐색증
망막색소변성증
포도막염
유리체 출혈
황반부종
중심성 장액성 망막증
증식성 유리체망막 증
제7장 지역별·국가별 분석
세계의 유리체망막 질환 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 유리체망막 질환 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
유리체망막 질환 시장 : 경쟁 구도
유리체망막 질환 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bayer AG
Novartis AG
GSK plc
Teva Pharmaceutical Industries Ltd.
Baxter International
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
Alcon Inc.
Bausch Health Companies Inc.
Santen Pharmaceutical Co. Ltd.
Topcon Corporation
Ocular Therapeutix Inc.
Carl Zeiss Meditec AG
EyePoint Pharmaceuticals Inc.
Kodiak Sciences Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
유리체망막 질환 시장 2029 : 새로운 기회를 제공하는 국가
유리체망막 질환 시장 2029 : 새로운 기회를 제공하는 부문
유리체망막 질환 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Vitreoretinal disorder encompasses a group of eye conditions that impact the retina and the vitreous humor, both of which are essential for preserving the eye's shape and ensuring visual clarity. These conditions can lead to progressive vision impairment and often require advanced diagnostic tools and specialized medical or surgical treatments for proper management.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of vitreoretinal disorders include retinal tears, retinal detachment, diabetic retinopathy, macular degeneration, macular holes, and others. A retinal tear is a small break or hole in the retina, the light-sensitive layer at the back of the eye. Diagnosis involves various techniques such as digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, among others. Treatment options include surgery, medication, and additional approaches. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and serve a range of end users including hospitals, home care settings, specialty clinics, and others.
The vitreoretinal disorder market research report is one of a series of new reports from The Business Research Company that provides vitreoretinal disorder market statistics, including vitreoretinal disorder industry global market size, regional shares, competitors with a vitreoretinal disorder market share, detailed vitreoretinal disorder market segments, market trends and opportunities, and any further data you may need to thrive in the vitreoretinal disorder industry. This vitreoretinal disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vitreoretinal disorder market size has grown strongly in recent years. It will grow from$4.30 billion in 2024 to $4.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of diabetic retinopathy, an aging population, increased awareness of retinal diseases, the expansion of healthcare infrastructure, and the early adoption of anti-vascular endothelial growth factor (VEGF) therapy.
The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to$6.30 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The projected growth in the forecast period can be attributed to the rising prevalence of age-related macular degeneration, an increasing incidence of diabetic retinopathy, growing investment in regenerative stem cell therapies, higher healthcare spending on eye diseases, greater awareness of early retinal disease detection, and supportive government initiatives. Key trends expected during this period include AI-powered retinal disease detection, robotic-assisted vitreoretinal surgeries, nanotechnology-based drug delivery systems, smart contact lenses for real-time eye monitoring, ultra-high-resolution adaptive optics imaging, and biodegradable intravitreal implants.
The increasing prevalence of diabetic retinopathy is expected to drive the growth of the vitreoretinal disorder market in the years ahead. Diabetic retinopathy is an eye disease resulting from damage to the retinal blood vessels caused by prolonged high blood sugar levels in individuals with diabetes. This condition is becoming more common due to the growing number of diabetes cases, largely fueled by sedentary lifestyles and inadequate blood sugar control, which lead to retinal vascular damage. Vitreoretinal disorder treatment is essential for managing diabetic retinopathy by addressing issues such as vitreous hemorrhage and tractional retinal detachment, thus helping to preserve vision and minimize further retinal harm. For example, in October 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that during 2022-23, 1.8% of screened First Nations individuals received treatment for diabetic retinopathy, with an age-standardized treatment rate of 1.3%, compared to 1.5% for non-Indigenous Australians. Therefore, the increasing incidence of diabetic retinopathy is contributing to the expansion of the vitreoretinal disorder market.
Leading companies in the vitreoretinal disorder market are developing advanced therapies, such as methotrexate-based treatments, to target primary vitreoretinal lymphoma-a rare and aggressive form of retinal cancer. This approach involves the intravitreal administration of methotrexate, a chemotherapy drug, to suppress cancerous cells in the retina and vitreous, providing a focused and effective treatment. For instance, in December 2022, Aldeyra Therapeutics Inc., a biotechnology company based in the U.S., announced a successful pre-New Drug Application (pre-NDA) meeting with the FDA regarding ADX-2191. This product is a novel, preservative-free methotrexate formulation designed to treat primary vitreoretinal lymphoma (PVRL), offering a promising solution for this rare condition.
In July 2024, Merck & Co. Inc., a U.S.-based pharmaceutical giant, acquired Eyebiotech Limited (EyeBio) for $3 billion. This strategic move aims to expand Merck's portfolio in the field of ophthalmology by adding Restoret (EYE103), a promising therapy for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Eyebiotech Limited, headquartered in the UK, is a clinical-stage biotech firm focused on developing treatments for retinal disorders, including vitreoretinal diseases.
Major players in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., and Clearside Biomedical.
North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in vitreoretinal disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vitreoretinal disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vitreoretinal disorder market includes revenues earned by entities by providing services such as diagnostic services, intravitreal injection therapies, imaging services, teleophthalmology consultations, postoperative care, and retinal rehabilitation services. The vitreoretinal disorder market also includes sales of fundus cameras, injections, and steroid implants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vitreoretinal Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vitreoretinal disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vitreoretinal disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vitreoretinal disorder market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Retinal Tear; Retinal Detachment; Diabetic Retinopathy; Macular Degeneration; Macular Hole; Other Types
2) By Diagnosis: Digital Fluorescein Angiography; Optical Coherence Tomography; Heidelberg Retinal Tomography; Indocyanine Green Angiography; Other Diagnosis
3) By Treatment: Surgery; Medication; Other Treatments
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vitreoretinal Disorder Market Characteristics
3. Vitreoretinal Disorder Market Trends And Strategies
4. Vitreoretinal Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Vitreoretinal Disorder Growth Analysis And Strategic Analysis Framework
5.1. Global Vitreoretinal Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Vitreoretinal Disorder Market Growth Rate Analysis
5.4. Global Vitreoretinal Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Vitreoretinal Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Vitreoretinal Disorder Total Addressable Market (TAM)
6. Vitreoretinal Disorder Market Segmentation
6.1. Global Vitreoretinal Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retinal Tear
Retinal Detachment
Diabetic Retinopathy
Macular Degeneration
Macular Hole
Other Types
6.2. Global Vitreoretinal Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Digital Fluorescein Angiography
Optical Coherence Tomography
Heidelberg Retinal Tomography
Indocyanine Green Angiography
Other Diagnosis
6.3. Global Vitreoretinal Disorder Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Medication
Other Treatments
6.4. Global Vitreoretinal Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
6.5. Global Vitreoretinal Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.6. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Tear, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atrophic Retinal Tear
Operculated Retinal Tear
Horseshoe Retinal Tear
Giant Retinal Tear
6.7. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Retinal Detachment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rhegmatogenous Retinal Detachment
Tractional Retinal Detachment
Exudative Retinal Detachment
6.8. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Diabetic Retinopathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Diabetic Macular Edema
6.9. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dry Macular Degeneration
Wet Macular Degeneration
6.10. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Macular Hole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Full-Thickness Macular Hole
Lamellar Macular Hole
Tractional Macular Hole
6.11. Global Vitreoretinal Disorder Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epiretinal Membrane
Retinal Vein Occlusion
Retinal Artery Occlusion
Retinitis Pigmentosa
Uveitis
Vitreous Hemorrhage
Macular Edema
Central Serous Retinopathy
Proliferative Vitreoretinopathy
7. Vitreoretinal Disorder Market Regional And Country Analysis
7.1. Global Vitreoretinal Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Vitreoretinal Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
